Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | GIPR | P48546 | 1/20 | 0.49 |
| ▸ | GRPR | P30550 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504805 | 0.96 | GRPR (0.52) | ERBB2IL23RKISS1RGRPR | |
| SCHEMBL30512700 | 0.90 | IL23R (0.54) | ERBB2IL23RKISS1RGLP1RGCGR | |
| SCHEMBL30444033 | 0.89 | ACE (0.54) | KISS1RERAP2ECE1MMP1GHSR | |
| SCHEMBL30392883 | 0.89 | RXFP1 (0.56) | IL23RERAP2GLP1RGCGRGIPR | |
| SCHEMBL30574266 | 0.88 | ERBB2 (0.56) | ERBB2ERAP2CCKBRGHSR | |
| SCHEMBL30885616 | 0.87 | ERAP2 (0.55) | KISS1RERAP2CCKBRMMP1 | |
| SCHEMBL30092926 | 0.87 | ACE (0.51) | IL23RKISS1RERAP2ECE1GHSR | |
| SCHEMBL30772214 | 0.87 | ERAP2 (0.64) | ERBB2ERAP2ECE1MMP1 | |
| SCHEMBL31267917 | 0.87 | ERAP2 (0.57) | KISS1RERAP2CCKBRECE1MMP1 | |
| SCHEMBL31232961 | 0.87 | IL23R (0.51) | IL23RKISS1RGRPRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025007890-A1 | NOVEL VACCINE DELIVERY SYSTEM | 厦门大学 | 2025-01-09 | — | — | WO | claimed |
| US-20250002848-A1 | TRANSDIFFERENTIATION OF NON-DERMAL PAPILLA CELLS TO DERMAL PAPILLA CELLS | DNOVO INC. | 2025-01-02 | — | — | US | claimed |
| US-20250002849-A1 | TRANSDIFFERENTIATION OF NON-HAIR FOLLICLE STEM CELLS TO NON-AUDITORY INDUCED HAIR FOLLICLE STEM CELLS | DNOVO INC. | 2025-01-02 | — | — | US | claimed |
| EP-4419648-A1 | TRANSDIFFERENTIATION OF NON-DERMAL PAPILLA CELLS TO DERMAL PAPILLA CELLS | dNovo Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023070026-A1 | TRANSDIFFERENTIATION OF NON-DERMAL PAPILLA CELLS TO DERMAL PAPILLA CELLS | DNOVO INC. (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2023034910-A1 | TRANSDIFFERENTIATION OF NON-HAIR FOLLICLE STEM CELLS TO NON-AUDITORY INDUCED HAIR FOLLICLE STEM CELLS | DNOVO INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-20220265837-A1 | COMPLEX FOR INTRACELLULAR DELIVERY OF MOLECULES | XIAMEN UNIVERSITY (CN) | 2022-08-25 | — | — | US | claimed |
| EP-4006057-A1 | COMPLEX FOR INTRACELLULAR DELIVERY OF MOLECULES | Xiamen University (CN) | 2022-06-01 | — | — | EP | claimed |
| EP-3478311-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | UNIV CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260108469-A1 | COMPOSITIONS COMPRISING WATER INSOLUBLE DRUGS AND METHODS OF PRODUCING AND USING SAME | NANO GHOST LTD (IL) | 2026-04-23 | — | — | US | disclosed |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260078156-A1 | TREATMENT OF NERVOUS SYSTEM INJURY AND NEURODEGENERATIVE DISORDERS AND RELATED CONDITIONS | CLEVELAND CLINIC FOUND (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4686758-A1 | NUCLEIC ACID FOR NUCLEAR TRANSLOCATION | 4basebio UK Ltd (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | BIO SYNTHESIS INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-114364378-A | Cancer immunotherapy | 阿克塞利阿肿瘤学私人有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11298319-B2 | Cell penetrating peptide (CPP)-mediated EV loading | EVOX THERAPEUTICS LTD (GB) | 2022-04-12 | — | — | US | disclosed |
| US-20220088131-A1 | COMPOSITIONS AND METHODS RELATING TO C5L2 | KING'S COLLEGE LONDON (GB) | 2022-03-24 | — | — | US | disclosed |
| US-11279941-B2 | Method for introducing protein into plant cell | RIKEN (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
| EP-3116898-B1 | AAV-EXPRESSED M013 PROTEIN AS AN ANTI-INFLAMMATROY THERAPEUTIC FOR USE IN A METHOD OF TREATING INFLAMMATORY OCULAR DISEASE | UNIV FLORIDA (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108469-A1 | COMPOSITIONS COMPRISING WATER INSOLUBLE DRUGS AND METHODS OF PRODUCING AND USING SAME | ABCB1, WEE1, PARP3 | ERBB2 451/4885IL23R 222/4885KISS1R 3548/4885 |
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | RNMT, ADAR, RNGTT | ERBB2 3124/4885IL23R 2125/4885KISS1R 4388/4885 |
| US-20260078156-A1 | TREATMENT OF NERVOUS SYSTEM INJURY AND NEURODEGENERATIVE DISORDERS AND RELATED CONDITIONS | SRPRB, SRPRA, SRP14 | ERBB2 2450/4885IL23R 820/4885KISS1R 4725/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | ERBB2 977/4885IL23R 388/4885KISS1R 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.